State Street Corp Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

State Street Corp increased its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 27.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,295 shares of the company’s stock after acquiring an additional 2,611 shares during the period. State Street Corp’s holdings in Structure Therapeutics were worth $540,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Sandia Investment Management LP acquired a new stake in Structure Therapeutics in the second quarter valued at $39,000. Assetmark Inc. grew its stake in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares during the last quarter. Quarry LP purchased a new position in Structure Therapeutics during the 2nd quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. raised its position in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after acquiring an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics in the third quarter valued at about $202,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Down 1.5 %

Shares of NASDAQ:GPCR opened at $27.76 on Friday. The company has a market cap of $1.59 billion, a P/E ratio of -37.51 and a beta of -2.78. The business has a fifty day simple moving average of $33.28 and a 200-day simple moving average of $37.18. Structure Therapeutics Inc. has a 52 week low of $25.90 and a 52 week high of $62.74.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on GPCR. Morgan Stanley initiated coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and a consensus target price of $86.50.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.